Weight loss
A dual-action weekly injection in late-stage trials for obesity and for liver disease caused by fat buildup.
Start here
Survodutide is an experimental once-weekly injection for obesity and metabolic liver disease that activates two hormone systems at once: GLP-1, which curbs appetite, and glucagon, which increases energy burn 3. In a Phase 2 obesity trial it produced up to 14.9% weight loss at 46 weeks 1, and in MASH (a form of fatty liver disease) 62% of people on the highest dose improved without their liver scarring getting worse, versus 14% on placebo 6. It has reached Phase 3 testing and holds an FDA Breakthrough Therapy designation for MASH with fibrosis, but it is still a research compound, not an approved medication.
Your body has two different hormone systems that affect your weight. GLP-1 (a gut hormone that tells your brain you're full) is a gut hormone that tells your brain you are full and slows how fast food leaves your stomach. Glucagon is a hormone that tells your body to burn more energy, including fat stored in the liver. Survodutide is built to switch on both at the same time: the GLP-1 side turns appetite down while the glucagon side turns energy burn up, raises your metabolic rate, and helps the liver burn off fat. Activating both together is designed to produce more weight loss and more liver benefit than drugs that work on only one of these systems.
Survodutide is a potent dual agonist (a compound that switches a receptor on), meaning it switches on two hormone receptors at once: the GLP-1 (a gut hormone that tells your brain you're full) receptor and the glucagon receptor. GLP-1 receptor activation promotes insulin release and lowers appetite. Glucagon receptor activation increases energy use and speeds up how the liver handles sugar and fat. Together the two actions add up to more weight loss. GLP-1 lowers appetite and slows stomach emptying. Glucagon raises energy burn, speeds up metabolism by turning on heat production in brown fat (a type of body fat that burns energy to make heat), and helps the liver burn fat. The combined result is better metabolic health than drugs that act on only one hormone.
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Weight Management
Up to 14.9% weight loss at 46 weeks through dual GLP-1R and GCGR activation — enhancing both appetite suppression and energy expenditure beyond GLP-1 alone
Metabolic Health
62% improvement in MASH (a fatty liver disease with inflammation) without worse scarring at 4.8 mg (vs 14% on placebo), liver fat cut by at least 30% in up to 67% (vs 14%), and broad metabolic gains including better blood sugar control and blood fat (lipid) levels
Blood Sugar Control
HbA1c (average blood sugar over about 3 months) drops of up to 1.71% in type 2 diabetes, with greater weight loss than semaglutide at the same blood sugar control
The most-asked question
Survodutide is dose-escalated: the studies start everyone low and step the dose up on a schedule, so the right amount depends on the week you're on. The research-reported maintenance range is 3.6 mg, once daily.
Starting dose, part of a 20-week step-up in dose
0.6 mg
Phase 2 starting dose; gradual escalation reduces GI side effects 1.
26 weeks of steady dosing after the dose has been raised step by step
3.6 mg
Maintenance dose in the phase 2 dose-finding trial; ~12.5% mean weight loss 1.
26 weeks of steady dosing after the dose has been raised step by step
4.8 mg
Highest dose studied; up to ~14.9% mean weight loss over 46 weeks 1.
The ceiling: 6 mg (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Survodutide:
Add the recommended volume of bacteriostatic water to the Survodutide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Survodutide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Survodutide's recorded schedule.
Injection sites & technique
Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Timing
Administer Survodutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
Survodutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Survodutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
In the phase 2 obesity trial, gastrointestinal adverse events affected 75% of survodutide-treated patients versus 42% on placebo 1; in the MASH trial, nausea itself affected 66% versus 23% 6. Dose-dependent and most pronounced during dose escalation. Odds ratio increases from 6.11 at 2.4 mg to 27.54 at 4.8 mg.
What to do Gradual dose escalation over 16-20 weeks significantly reduces nausea incidence and severity. Smaller meals, avoiding high-fat foods, and adequate hydration help. Symptoms typically diminish with continued treatment.
Frequently accompanies nausea during dose escalation. Dose-dependent occurrence related to dual GLP-1R and GCGR activation in the gastrointestinal tract and central nervous system.
What to do Slower dose titration (stepping the dose up gradually). Anti-emetics if needed. Ensure hydration. May temporarily hold dose escalation if severe.
Gut upset from the drug acting on two hormone docking sites, which changes how the gut moves and secretes. Generally mild to moderate.
What to do Maintain hydration. Usually resolves with continued treatment. Dose adjustment if persistent.
Expected pharmacological effect contributing to weight loss. Mediated through both GLP-1R and GCGR central nervous system effects on appetite regulation.
What to do Generally beneficial for the treatment goal. Ensure adequate nutritional intake despite reduced appetite. Monitor for excessive caloric restriction.
Worth knowing about, but most people never see these.
Less common gut effects. They may come from changes in how the gut moves when two hormone docking sites are switched on.
What to do Dietary fiber, adequate hydration, and gentle physical activity. Usually transient and manageable.
Rare, but if any of these happen, stop and contact a medical professional.
A rare but serious risk shared by the whole GLP-1 (a gut hormone that tells your brain you're full) drug class. Watch for severe abdominal pain that does not go away.
What to do Discontinue survodutide immediately if pancreatitis is suspected. Seek emergency care for severe abdominal pain radiating to the back. Do not restart treatment if pancreatitis is confirmed.
Week by week
Is it right for you?
Survodutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Switches on the same GLP-1 (a gut hormone that tells your brain you're full) receptor twice, with no added benefit and more stomach and gut side effects.
Higher risk of low blood sugar (hypoglycemia (low blood sugar)) when combined with drugs that push the body to release insulin regardless of blood sugar level.
Survodutide's glucagon receptor activation may change how injected glucagon (used in emergencies for low blood sugar) works.
Works in a complementary way by helping the body respond to insulin, and has well-established heart benefits. This supports complete care of blood sugar and metabolism.
Lowers blood sugar on its own and protects the heart and kidneys by separate routes, adding to survodutide's metabolic and liver benefits.
Cutting calories works together with survodutide's lower appetite and higher energy burn for the most weight loss.
Generally safe to take alongside Survodutide. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Survodutide is particularly well-suited for people who want stronger metabolic results from a drug that acts on two hormone docking sites at once. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Survodutide data comes from Phase 2 obesity and MASH (a fatty liver disease with inflammation) trials. Stomach and gut side effects rise with the dose: 75% on survodutide vs 42% on placebo in the obesity trial 1; nausea 66%, diarrhea 49% and vomiting 41% in the MASH trial 6. They mirror the GLP-1 (a gut hormone that tells your brain you're full) drug class but happen more often, because the glucagon part also raises energy burning. Pancreatitis (inflamed pancreas) is a risk, as with all GLP-1 drugs. A baseline lipase test (a blood test for the pancreas) and teaching patients the warning sign (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma (a rare thyroid cancer) risk is theoretical, based on the GLP-1 class, but rules out use in MEN 2 or with a personal history of thyroid cancer.
Phase 2 safety data in about 400 patients supports tolerability for up to 48 weeks, though data beyond 1 year is limited before any approval. Trials of heart outcomes and long-term liver safety monitoring in MASH patients are ongoing. It is not yet FDA-approved, so all use remains investigational until Phase 3 is complete.
Keeping it good
Store Survodutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Survodutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2024
Survodutide, a dual glucagon/GLP-1 agonist (it switches on both hormone receptors), reduced body weight by 6-15% in a dose-dependent way (the most at higher doses) in 46-week Phase 2 (mid-stage) obesity trials.
le Roux CW, Steen O, Lucas KJ, et al.
2024
Research (2024) on survodutide contributes important scientific knowledge about its biological and pharmacological properties.
Blüher M, Rosenstock J, Hoefler J, et al.
2022
Research (2022) demonstrates survodutide's efficacy in clinical treatment and therapeutic applications.
Zimmerman T, et al.
2024
Clinical evidence (2024) supports the therapeutic use of survodutide in medical treatment protocols.
Kosiborod MN, Platz E, Wharton S, et al.
2024
Clinical trial (2024) provides evidence for survodutide's effectiveness in therapeutic management.
Thomas L, Martel E, Rist W, et al.
2024
48-week phase 2 (mid-stage) trial in 293 adults with biopsy-confirmed MASH (a serious fatty liver disease with inflammation) and F1-F3 fibrosis (mild to advanced liver scarring), randomised to weekly survodutide 2.4, 4.8 or 6.0 mg or placebo. Improvement in MASH with no worsening of fibrosis: 47%, 62% and 43% vs 14% on placebo. Liver fat fell by at least 30% in 63%, 67% and 57% vs 14%; fibrosis improved by at least one stage in 34%, 36% and 34% vs 22%. Nausea 66% vs 23%, diarrhoea 49% vs 23%, vomiting 41% vs 4%; serious adverse events 8% vs 7%.
Sanyal AJ, Bedossa P, Fraessdorf M, et al.
If this isn't the right fit
Your questions
Survodutide switches on both the GLP-1 (a gut hormone that tells your brain you're full) receptor AND the glucagon receptor, while semaglutide only switches on the GLP-1 receptor. The glucagon part adds a different effect: it burns more energy, helps the liver burn fat, and produces more body heat. In a head-to-head Phase 2 comparison in people with type 2 diabetes, survodutide produced greater weight loss (8.7% vs 5.3%) than semaglutide at the same level of blood sugar control.
The FDA granted survodutide Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis. This was based on Phase 2 data showing improvement in MASH without worsening of fibrosis in 62% of patients at the 4.8 mg dose, compared to 14% with placebo 6. This designation accelerates the development and regulatory review process.
Survodutide is currently in Phase 3 clinical trials. The SYNCHRONIZE obesity program and LIVERAGE MASH program are expected to report results in 2026-2027. Regulatory submissions could follow positive Phase 3 results, with potential approval estimated for 2027-2028, though timelines depend on trial outcomes and regulatory review.
Survodutide switches on both the GLP-1 (a gut hormone that tells your brain you're full) and glucagon receptors (hormone docking sites) in the gut and the brain. That has stronger effects on gut movement, stomach emptying, and appetite signals than drugs that act on GLP-1 alone. In the phase 2 obesity trial, stomach and gut side effects affected 75% of patients versus 42% on placebo 1. In the MASH trial (MASH is a fatty liver disease with inflammation), nausea affected 66% versus 23% 6. However, raising the dose gradually over 16-20 weeks greatly reduces these effects, and most patients tolerate the medication well at maintenance doses.
Yes. The glucagon part does not worsen blood sugar control because the GLP-1 (a gut hormone that tells your brain you're full) part balances it by helping the body release insulin only when blood sugar is high. In Phase 2 diabetes trials, survodutide lowered HbA1c (average blood sugar over about 3 months) about as much as semaglutide while producing more weight loss. The two actions appear to work together rather than against each other.
Several Phase 3 programs are underway: SYNCHRONIZE-1 (obesity without diabetes, n=726), SYNCHRONIZE-2 (obesity with T2DM, n=755), SYNCHRONIZE-CVOT (cardiovascular outcomes, n=5,531), LIVERAGE (MASH with fibrosis, n=1,800), and regional trials in China and Japan. These represent one of the largest clinical development programs for a metabolic disease agent.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Survodutide research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Survodutide is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek